Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Goetz

Showing results (151-160 of 265) with videos related to

Pageof 27
Sort By:
Steroids|August 28, 2014
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozoleJames N Ingle, Krishna R Kalari, Aman U Buzdar, et al.
Cancer Science|March 9, 2021
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trialsMasakazu Toi, Kenichi Inoue, Norikazu Masuda, et al.
NPJ Breast Cancer|September 1, 2017
Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the <i>ZNF423</i> and <i>CTSO</i> genesDuan Liu, Ming-Fen Ho, Daniel J Schaid, et al.
Cancer Research|April 1, 2010
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancerJames N Ingle, Aman U Buzdar, Daniel J Schaid, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Molecular Cancer|January 16, 2024
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancerHeba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, et al.
Clinical Pharmacology and Therapeutics|February 1, 2018
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen TherapyMatthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, et al.
Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2012
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8Matthew P Goetz, Vera J Suman, Tanya L Hoskin, et al.
NPJ Breast Cancer|March 30, 2024
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancerRoberto A Leon-Ferre, Jodi M Carter, David Zahrieh, et al.
Pageof 27

Showing results (151-160 of 265) with videos related to

Sort By:
Pageof 27
Steroids|August 28, 2014
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozoleJames N Ingle, Krishna R Kalari, Aman U Buzdar, et al.
Cancer Science|March 9, 2021
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trialsMasakazu Toi, Kenichi Inoue, Norikazu Masuda, et al.
NPJ Breast Cancer|September 1, 2017
Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the <i>ZNF423</i> and <i>CTSO</i> genesDuan Liu, Ming-Fen Ho, Daniel J Schaid, et al.
Cancer Research|April 1, 2010
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancerJames N Ingle, Aman U Buzdar, Daniel J Schaid, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Molecular Cancer|January 16, 2024
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancerHeba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, et al.
Clinical Pharmacology and Therapeutics|February 1, 2018
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen TherapyMatthew P Goetz, Katrin Sangkuhl, Henk-Jan Guchelaar, et al.
Future Oncology (London, England)|October 12, 2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancerCiara C O'Sullivan, Karla V Ballman, Linda McCall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2012
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8Matthew P Goetz, Vera J Suman, Tanya L Hoskin, et al.
NPJ Breast Cancer|March 30, 2024
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancerRoberto A Leon-Ferre, Jodi M Carter, David Zahrieh, et al.
Pageof 27